Articles tagged "Kidney transplantation"

2021 American Transplant Congress
Impact of Once-Daily Extended-Release Tacrolimus Intrapatient Variability in Stable Adolescent and Young Adult Renal Transplant Recipients – 3 Year Results
M. M. Chandran¹, E. Blanchette¹, J. Goebel², M. Bock¹
¹Children's Hospital Colorado, Denver, CO, ²Helen DeVos Children’s Hospital, Grand Rapids, MI
*Purpose: Successful renal transplantation requires complex medication regimens that rely heavily on strict adherence to be effective. Variability in immunosuppression exposure, specifically tacrolimus, is associated…
2021 American Transplant Congress
Graft Outcomes of Antibody Mediated Rejection without Donor Specific Anti – HLA Antibodies After Kidney Transplantation
H. Ko, S. Min, A. Han, S. Ahn, C. T. Chung, H. Kim, K. Choi, S. Min, H. Kang, J. Ha
Seoul National University Hospital, Seoul, Korea, Republic of
*Purpose: The aim of this study was to investigate graft outcomes based on the presence of donor-specific anti-HLA antibodies (DSA) and the time of diagnosis…
2021 American Transplant Congress
Changes in Glomerular Filtration Rate (delta Egfr) within the First Year Predict Long-Term Outcomes of Renal Grafts
A. M. Thompson, M. Zenati, S. Hariharan, M. Molinari
Starzl Transplant Institute, UPMC, Pittsburgh, PA
*Purpose: The relationship between changes in eGFR (Delta eGFR) during the first year after renal transplantation (RT) and long-term graft survival are poorly understood. We…
2021 American Transplant Congress
Review of Outcomes After Diagnosis of Malignancy in Kidney Transplant Patients: Unos Database
H. Patel¹, N. Agrawal¹, R. Gupta¹, P. Geetha², A. Abdul Razzack³, F. Cardarelli¹
¹Transplant Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, ²Nephrology, Beth Israel Deaconess Medical Center, Boston, MA, ³Medicine, Dr. NTR University of Health Sciences, Vijaywada, India
*Purpose: Malignancy is the third major cause of death among transplant recipients. Among the transplant recipients, Patient and kidney transplant outcomes after the diagnosis of…
2021 American Transplant Congress
Transplant Data Platform – An Augmented Clinical Intelligence Framework
C. Focht, W. Tian, J. Zeng, N. Dzebisashvili, S. Ghosh
CareDx, Brisbane, CA
*Purpose: UNOS, SRTR, USRDS registries are rich in patient baseline data. However, all suffer from data attrition as patients move further out post-transplant or between…
2021 American Transplant Congress
Kidney Transplantation in Times of Covid-19 – Decision Analysis in the Canadian Context
I. Yanev¹, M. Gagnon¹, M. Cheng², S. Paraskevas², D. Kumar³, A. Dragomir⁴, R. Sapir-Pichhadze⁴
¹McGill University, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Research Institute of McGill University Health Centre, Montreal, QC, Canada
*Purpose: The coronavirus disease 2019 (COVID-19) pandemic significantly impacted the field of transplantation across Canada. In this study, we outline the implications of COVID-19 related…
2021 American Transplant Congress
Kidney Transplantation in Very Highly-Sensitized Patients with Maastricht Type III Non-heart-Beating Donors
F. Villanego¹, A. Mazuecos¹, L. Vigara¹, V. Lopez², G. Bernal³, A. Rodriguez-Benot⁴, M. de Gracia⁵, P. Castro⁶, A. Alvarez⁶
¹Department of Nephrology, Hospital Puerta del Mar, Cadiz, Spain, ²Department of Nephrology, Hospital Carlos Haya, Malaga, Spain, ³Department of Nephrology, Hospital Virgen del Rocio, Sevilla, Spain, ⁴Department of Nephrology, Hospital Reina Sofia, Cordoba, Spain, ⁵Department of Nephrology, Hospital Virgen de las Nieves, Granada, Spain, ⁶Andalusian Transplant Coordination, Sevilla, Spain
*Purpose: In 2012, a kidney transplant (KT) program for very highly-sensitized (VHS) patients (PRA ≥ 95%) based on virtual crossmatch began in Andalusia (Spanish region).…
2021 American Transplant Congress
Long Term Safety and Efficacy of Tocilizumab (anti-il6r, Tcz) Therapy in the Treatment of Refractory Chronic Antibody Mediated Rejection (cabmr) in 25 Pediatric Renal Transplant Recipients
M. Pearl¹, P. Weng¹, A. Dokras², H. Pizzo³, J. Garrison³, C. Butler¹, J. Q. Zhang¹, K. Lim³, E. Reed¹, I. Kim³, M. Haas³, X. Zhang³, R. Ettenger¹, S. Jordan³, D. Puliyanda³
¹Pediatric Nephrology, UCLA Medical Center, Los Angeles, CA, ²Pediatric Nephrology, UT South Western, Dallas, CA, ³Pediatric Nephrology, Cedars Sinai Medical Center, West Hollywood, CA
*Purpose: Development of de novo donor specific antibodies (DSA) post renal transplantation puts pediatric patients at risk for chronic Antibody Mediated Rejection (cABMR) and allograft…
2021 American Transplant Congress
An HLA Class II Matching Strategy That Predicts De Novo Donor-specific HLA Antibody Formation Using Low Resolution HLA Types
L. Hidalgo¹, I. Martinez Juarez², L. Morales Buenrostro², S. Shojai³, P. Campbell¹
¹University of Wisconsin Madison, Madison, WI, ²Instituto Nacional de Ciencias Medicas Y Nutricion Salvador Zubrian, Mexico City, Mexico, ³Medicine, University of Alberta, Edmonton, AB, Canada
*Purpose: The development of de novo donor-specific HLA antibodies (dnDSA) is predominantly against HLA-Class II antigens and is a function of the degree of HLA-DQ…
2021 American Transplant Congress
Additional Value to Participation in a National Paired Kidney Exchange Program: Exploring Characteristics of Chain End Living Donors and Waitlist Recipients
N. Osbun¹, A. Thomas², M. Cooper³, S. Flechner⁴, D. Segev², J. Veale¹
¹Urology, University of California Los Angeles, Los Angeles, CA, ²Johns Hopkins University, Baltimore, MD, ³Medstar Georgetown Transplant Institute, Washington DC, DC, ⁴Cleveland Clinic, Cleveland, OH
*Purpose: Non-directed kidney donors can initiate living donor chains that end to patients on the deceased donor waitlist. While many studies of paired exchange practices…